Tamtam Try Tamtam free
Werfen logo

Werfen account plan

Specialized diagnostics worldwide leader

At a glance

Werfen is a family-owned Barcelona in-vitro diagnostics group with FY2025 sales of €2.1 billion and 7,131 employees.

Werfen is a family-owned specialized in-vitro diagnostics (IVD) group founded in 1966 in Barcelona. It develops, manufactures and distributes instruments, reagents and data management solutions in Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity and Transplant for hospitals, hospital networks, commercial and reference laboratories and blood donor centers. It has direct operations in 30 countries, distributors in more than 100 territories and 7,131 employees at year-end 2025. FY2025 sales were €2,131M (+3.3% at constant exchange rate and perimeter) with EBITDA of €473M (22% margin); 95% of revenue is recurring, on an installed base of 99,895 active instruments.

Business units

Strategic priorities

3-Year Strategic Plan 2025-2027
2025 was year one of "Solidifying for Growth", which strengthens mission-critical functions (cybersecurity, compliance, quality and regulatory), facilities and talent. The CEO's target is to be stronger in organization, innovation and financial strength by the end of 2027.
Digital as a third pillar
In 2026 the CEO wants Digital to stand alongside instruments and reagents. Digital Solutions built a production-ready cloud foundation for future SaaS offerings and obtained Spain's ENS cybersecurity certification.
Project CODE
A single Commercial Operations Digital Ecosystem that integrates sales, marketing, service and applications.
Deleveraging
The CFO's primary commitment for 2026 is to continue deleveraging and keep ample operating liquidity; Net Debt-to-EBITDA rose to 3.5x in 2025 from 3.0x.
North America large accounts
In 2026 North America will target large health systems, reference labs, GPOs and donor centers. The region is the largest at 37% of sales (€790M, +8%) and created an Automation and IT Solutions division.

Latest results

Werfen's latest published figures are for FY2025 (released 9 April 2026); no H1 2026 report is public. Sales were €2,131M, up 3.3% at constant exchange rate and perimeter, and up 6% excluding China, with North America +8%, Latin America +10% and EEMEA +7%. EBITDA fell to €473M (22% margin) from €545M (25%) in 2024, which the CFO called a year of adjustment. Net debt was €1,661M vs €1,617M, and a €500 million bond extended maturities while the Investment Grade rating was kept. No numeric guidance is given; the CFO expects 2026 to remain challenging.

Investments and deals

R&D
Record R&D investment of €190M in 2025 (9% of sales, +8% vs 2024), with 900+ R&D employees; launches include the ACL TOP Family 70 Series and the GEM Premier 7000 with iQM3.
US facilities
A new North America Distribution Center in Devens, MA (more than 230,000 sq. ft.), the acquired 130,536 sq. ft. San Diego Whole Blood Hemostasis Technology Center, and nearly 10,000 m² of added R&D and manufacturing space in Bedford.
Werfen-Seegene joint venture
A joint venture with Seegene to develop and manufacture molecular diagnostics at the Lliçà d'Amunt site.
Portfolio moves
Immucor (2023) created the Transfusion and Transplant lines, Omixon was acquired in 2024, and the Medical Devices distribution business was divested in July 2024.

Challenges and risks

China market correction
Diagnostic stewardship and reimbursement policy in China cut prices and volumes; China sales (€187M) fell vs 2024.
Margin and leverage
EBITDA margin fell to 22% from 25% and Net Debt-to-EBITDA rose to 3.5x from 3.0x.
Tariffs and currency
Trade tensions, higher tariff costs and unfavorable foreign exchange weighed on 2025.
European lab budgets
Europe grew 3.6% amid fiercely competitive conditions and tighter lab spending.
Regulation and cybersecurity
IVDR, software-as-a-medical-device regulation, product cybersecurity and software obsolescence are named risks.

What leadership says

“We haven't hit the brakes on our plans; on the contrary, we have continued to invest with a forward-looking vision.”

Alejandro Risso, CEO · FY2025 results release, 9 April 2026

“Our capital structure is exceptionally resilient.”

Javier Gómez, CFO · FY2025 results release, 9 April 2026

“Looking to 2026, we expect continued global turbulence”

Marc Rubiralta, Chairman · Werfen Annual Review 2025, April 2026

“By the end of 2027, we will be a stronger company in terms of our organization, innovation and financial strength”

Alejandro Risso, CEO · CEO interview, Werfen Annual Review 2024, April 2025

Where a supplier can help

Commercial platform for Project CODE
Unifying sales, marketing, service and applications into one digital ecosystem opens room for CRM, service-management and data-integration suppliers.
Cloud, SaaS and cybersecurity
The Digital third pillar, the cloud foundation for SaaS offerings and new leadership in cybersecurity point to needs in cloud engineering, security and software-as-a-medical-device compliance tooling.
Cost and cash discipline
With leverage at 3.5x and deleveraging the 2026 priority, offers that lower operating cost or improve cash generation fit the CFO's agenda better than new spend.
Logistics and facilities in the US
The Devens distribution center, San Diego site and Bedford expansion create needs in warehouse operations, cold-chain and facility services.
Compliance and quality systems
New Chief Compliance Officer and Global Risk Officer roles plus IVDR work suggest demand for compliance, quality and regulatory tooling.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Werfen?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Werfen

What does Werfen do?

Werfen develops, manufactures and distributes in-vitro diagnostic instruments, reagents and data management solutions in Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity and Transplant, for hospitals, laboratories and blood donor centers.

What is Werfen's revenue?

FY2025 sales were €2,131M, up 3.3% at constant exchange rate and perimeter, with EBITDA of €473M.

How many employees does Werfen have?

Werfen had 7,131 employees at year-end 2025, with direct operations in 30 countries.

Who leads Werfen?

Alejandro Risso, formerly President of Clinical Diagnostics at Thermo Fisher Scientific, is CEO; Marc Rubiralta chairs the board and Javier Gómez is CFO. Werfen is family-owned.

What is Werfen's strategy?

The 2025-2027 plan "Solidifying for Growth" strengthens the organization, specialization and digital, while the 2026 financial priority is deleveraging.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)